IRIS Institutional Research Information System - OPENBS Open Archive UniBS

BELLUCCI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.607
EU - Europa 4.089
AS - Asia 3.180
SA - Sud America 577
AF - Africa 63
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
Totale 13.533
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.518
PL - Polonia 1.624
CN - Cina 1.087
SG - Singapore 1.048
UA - Ucraina 569
IT - Italia 550
BR - Brasile 497
DE - Germania 420
HK - Hong Kong 374
FI - Finlandia 226
VN - Vietnam 225
GB - Regno Unito 170
RU - Federazione Russa 128
TR - Turchia 122
IE - Irlanda 109
FR - Francia 108
IN - India 103
CA - Canada 46
BD - Bangladesh 39
ID - Indonesia 33
MX - Messico 32
SE - Svezia 31
AR - Argentina 28
KR - Corea 28
CZ - Repubblica Ceca 26
BE - Belgio 25
NL - Olanda 25
ZA - Sudafrica 21
JP - Giappone 17
AT - Austria 16
ES - Italia 16
IQ - Iraq 16
EC - Ecuador 14
AU - Australia 11
IL - Israele 11
PK - Pakistan 10
AZ - Azerbaigian 9
EG - Egitto 9
KE - Kenya 9
PY - Paraguay 8
UZ - Uzbekistan 8
VE - Venezuela 8
CO - Colombia 7
MA - Marocco 7
AE - Emirati Arabi Uniti 6
IR - Iran 6
JO - Giordania 6
LT - Lituania 6
BG - Bulgaria 5
CH - Svizzera 5
CL - Cile 5
EU - Europa 5
PT - Portogallo 5
TN - Tunisia 5
BY - Bielorussia 4
KZ - Kazakistan 4
AM - Armenia 3
BO - Bolivia 3
DK - Danimarca 3
EE - Estonia 3
ET - Etiopia 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
MU - Mauritius 3
PE - Perù 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
DO - Repubblica Dominicana 2
DZ - Algeria 2
GT - Guatemala 2
JM - Giamaica 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LV - Lettonia 2
NP - Nepal 2
OM - Oman 2
PS - Palestinian Territory 2
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
GE - Georgia 1
GY - Guiana 1
KW - Kuwait 1
LK - Sri Lanka 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
QA - Qatar 1
RO - Romania 1
SL - Sierra Leone 1
Totale 13.531
Salva come PNG Salva come JPEG
Città #
Warsaw 1.620
Fairfield 561
Singapore 499
Ashburn 465
Woodbridge 427
Jacksonville 421
Hong Kong 373
Chandler 292
Dearborn 270
Beijing 256
Houston 249
Cambridge 245
Seattle 223
Brescia 211
Ann Arbor 207
Wilmington 201
Princeton 192
New York 156
Nanjing 144
Helsinki 135
Dublin 108
Los Angeles 101
Munich 100
Istanbul 93
Dong Ket 66
The Dalles 61
Milan 60
Des Moines 58
Ho Chi Minh City 57
Dallas 56
São Paulo 52
Buffalo 50
Jinan 50
Moscow 48
Nanchang 48
San Francisco 47
Changsha 41
Hebei 40
Shenyang 39
Chicago 38
Shanghai 38
Pune 36
Tianjin 34
Boardman 32
Santa Clara 32
Redondo Beach 31
Hanoi 30
San Diego 30
Jakarta 27
Turku 27
London 26
Brussels 24
Denver 24
Kunming 23
Toronto 23
Brno 18
Nuremberg 18
Phoenix 18
Jiaxing 17
Ningbo 17
Rio de Janeiro 17
Rome 17
Guangzhou 16
Taizhou 16
Tokyo 16
Frankfurt am Main 15
Lappeenranta 14
Zhengzhou 14
Hangzhou 13
Poplar 13
San Giuliano Milanese 13
Tucson 13
Ankara 12
Verona 12
Atlanta 11
Brooklyn 11
Hefei 11
Lanzhou 11
Norwalk 11
Orem 11
Stockholm 11
Belo Horizonte 10
Brasília 10
Dhaka 10
Johannesburg 10
Lancaster 10
Mexico City 10
Salò 10
Baku 9
Haiphong 9
Nairobi 9
Romola 9
San Donà Di Piave 9
Boston 8
Kocaeli 8
Manchester 8
Montreal 8
Porto Alegre 8
Taiyuan 8
Tashkent 8
Totale 9.334
Salva come PNG Salva come JPEG
Nome #
Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose Deprivation 336
Anionic liposomes for siRNA delivery to primary neuronal cells: evaluation of Alpha synuclein knockdown efficacy 320
Redistribution of DAT/α-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease 293
Dopamine transporter/α-synuclein complexes are altered in the post mortem caudate putamen of Parkinson’s disease: An in situ proximity ligation assay study 288
NF-κB in Innate Neuroprotection and Age-Related Neurodegenerative Diseases 266
The End Is the Beginning: Parkinson's Disease in the Light of Brain Imaging 255
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. 253
Mild inflammatory profile without gliosis in the c-rel deficient mouse modeling a late-onset parkinsonism 251
The Contribution of -Synuclein Spreading to Parkinson’s Disease Synaptopathy 248
INDUCTION OF INFLAMMATORY MEDIATORS AND MICROGLIAL ACTIVATION IN MICE TRANSGENIC FOR MUTANT P301S TAU PROTEIN 243
The "in situ" proximity ligation assay to probe protein-protein interactions in intact tissues 210
Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure 204
Living in promiscuity: The multiple partners of alpha-synuclein at the synapse in physiology and pathology 204
Mitochondria and alpha-synuclein: Friends or foes in the pathogenesis of Parkinson's disease? 200
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains 192
Alpha-Synuclein Preserves Mitochondrial Fusion and Function in Neuronal Cells 188
NF-κB/c-Rel deficiency causes Parkinson's disease-like prodromal symptoms and progressive pathology in mice 183
Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate 183
c-Rel deficient mice, a mouse model of "spreading" PD-like pathology. 180
Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation 177
Abiraterone acetate exerts a cytotoxic effect in human prostate cancer cell lines 168
The proximity ligation assay: an high throughput technique for protein analysis in neuroscience 163
α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons 158
Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases 158
From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinson's disease 155
Depletion of Progranulin Reduces GluN2B-Containing NMDA Receptor Density, Tau Phosphorylation, and Dendritic Arborization in Mouse Primary Cortical Neurons 154
Point mutated Caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature 152
Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy 151
EFFECT OF SUBCHRONIC ADMINISTRATION OF METRIFONATE, RIVASTIGMINE AND DONEPEZIL ON BRAIN ACETYLCHOLINE IN AGED F344 RATS 151
c-Rel deficient mice, a mouse model of “spreading” PD-like pathology 150
DIFFERENTIAL ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE SIGNALLING PATHWAYS IN THE HIPPOCAMPUS OF CRND8 TRANSGENIC MOUSE, A MODEL OF ALZHEIMER'S DISEASE 148
Synapsin III alterations in Parkinson's disease 147
Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer 146
ALPHA-SYNUCLEIN MODULATES SYNAPSIN III IN NIGROSTRIATAL DOPAMINERGIC NEURONS: IMPLICATIONS FOR PARKINSON'S DISEASE 145
Mitochondrial Dysfunction and Alpha-Synuclein Synaptic Pathology in Parkinson’s Disease: Who’s on First? 145
Involvement of Synapsin III in the onset of alpha-synuclein synaptic pathology in Parkinson’s disease 135
Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease 126
ABNORMAL PROCESSING OF TAU IN THE BRAIN OF AGED TGCRND8 MICE 125
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. 124
Design and Synthesis of Fluorescent Methylphenidate Analogues for a FRET-Based Assay of Synapsin III Binding 124
COMBINED TREATMENT WITH ATORVASTATIN AND MINOCYCLINE SUPPRESSES SEVERITY OF EAE 122
Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. 120
Alpha-synuclein modulates the localization, expression and function of NR2B-containing NMDA receptors: implications in the pathogenesis of Parkinson's disease 119
Synapsin III Alteration in Parkinson's disease 119
Involvement of Synapsin III in the onset of Alpha-synuclein pathology in Parkinson’s Disease 119
PGRN gene silencing in primary neuronal cultures: a model of FTLD-U 119
Alpha-synuclein and NMDA receptors: a novel postsynaptic couple playing a pivotal role in the regulation of the functional activity of nigral dopaminergic neurons 118
Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of Parkinson’s disease and dementia with Lewy bodies, 116
AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons of Synapsin III knockout mice reveals novel molecular features involved in Parkinson's disease pathology. 115
Synapsin III Alteration in Parkinson's disease 115
NF-κB unbalance and dysfunction in acute and age-related neurodegenerative disease 112
CHOLINERGIC DYSFUNCTION, NEURONAL DAMAGE AND AXONAL LOSS IN TGCRND8 MICE 111
Alpha-synuclein aggregation in dopaminergic cells is modulated by glucose metabolism 111
Alpha-Synuclein in the Regulation of Brain Endothelial and Perivascular Cells: Gaps and Future Perspectives 110
Role of dopamine D3R/nAChR heterodimeric complex in the regulation of dopaminergic neurons function. 109
Synapsin III knock-out reduces AAV-alpha-synuclein overexpression-related neuropathology in the nigrostriatal system 109
Synapsin III and Alpha-Synuclein cooperation in the onset of synaptic pathology in Parkinson’s Disease 109
Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson’s disease 107
Parkinson's disease: from synaptic loss to connectome dysfunction 106
Exploring LRRK2-dependent clearance of α-synuclein pffs in glial cells via clusterin 106
Role of dopamine D3R and acetylcholine nicotinic receptor interaction in the regulation of dopaminergic neurons function. 105
Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes 105
Study of alpha-synuclein fibrillation: State of the art and expectations 102
The good and bad of therapeutic strategies that directly target α-synuclein 102
Selective dopaminergic alpha-synuclein pathological changes following glucose deprivation "in vitro": implications for Parkinson's disease 101
ANALOGHI STRUTTURALI DEL METILFENIDATO COME AGENTI DISEASE-MODIFYING DELLA MALATTIA DI PARKINSON 97
Effects of rofecoxib treatment on brain inflammatory reaction and cholinergic function in beta-(1-42) injected rats into the nucleus basalis 96
An updated reappraisal of synapsins: structure, function and role in neurological and psychiatric disorders 96
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson’s disease 94
. Alpha-synuclein is a crucial mediator of mitochondrial fusion and functions 94
BETA-AMYLOID INFLAMMATION AND CHOLINERGIC HYPOFUNCTION IN THE RAT BRAIN IN VIVO: INVOLVEMENT OF P38MAPK PATHWAY 92
Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. 92
MicroRNA‑34a‑5p expression in the plasma and its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study 92
Neuroprotective epi-drugs quench the inflammatory response and microglial/macrophage activation in a mouse model of permanent brain ischemia 92
Non-steroid antiinflammatory agents (nsaids): are they a valid approach to Alzheimer’s disease prevention? 91
Redistribution of DAT/alpha-synuclein complexes visualized "in situ" by proximity ligation assay in a transgenic mouse model of Parkinson's disease 90
NF-κB/c-Rel DNA-binding is reduced in substantia nigra and peripheral blood mononuclear cells of Parkinson's disease patients 86
In vivo effects of NSAIDs on amyloid beta(1-42)-induced brain neurotoxicity 84
Targeting α-Synuclein-Related Synaptic Pathology: Novel Clues for Parkinson’s Disease Therapy 82
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and synaptic protein’s redistribution 82
Alpha-synuclein absence affected mitochondrial fusion and functions 82
Alpha-Synuclein is Involved in DYT1 Dystonia Striatal Synaptic Dysfunction 81
THE SELECTIVE CYCLOOXIGENASE-2 INHIBITOR ROFECOXIB SUPPRESSES BRAIN INFLAMMATION AND PROTECTS CHOLINERGIC NEURONS FROM EXCITOTOXIC DEGENERATION IN VIVO 81
Ex vivo characterization of progranulin gene silencing in primary neuronal cultures to study the biological basis of FTLD-U 81
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease 81
NSAIDs in Animal Models of Alzheimer's disease 79
Neuroprotective effects of D2/D3 agonists in an "in vitro" model of dopaminergic degeneration 78
Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson's disease 77
Effects of novel NSAIDs on brain inflammation and release of neurotrasmitters in animal models of neurodegeneration 77
NSAIDs in animal models of Alzheimer’s Disease 76
Induction of the Unfolded Protein Response by alpha-synuclein in experimental models of Parkinson's disease 75
Novel perspectives for Parkinson’s disease therapy: insights from the latest advances in disease pathophysiology, diagnostic and experimental tools and molecular targets 75
Nuovi Aspetti di Fisiopatologia del DLB e PDD 74
NSAIDs in animal models of Alzheimer's disease 74
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy? 73
EXPERIMENTAL BRAIN INFLAMMATION AND NEURODEGENERATION AS MODEL OF ALZHEIMER'S DISEASE: PROTECTIVE EFFECTS OF SELECTIVE COX-2 INHIBITORS 73
The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders 71
Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice 70
COMPARISON BETEWEEN FLURBIPROFEN AND ITS NITRIC OXIDE-RELEASING DERIVATIVES HCT-1026 AND NCX-2216 ON ABETA(1-42)-INDUCED BRAIN INFLAMMATION AND NEURONAL DAMAGE IN THE RAT 65
Validation of synapsin III as a therapeutic target for Parkinson’s disease in the AAV-mediated alpha-synuclein mouse model 65
Totale 13.254
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.601
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.070 0 0 0 0 0 160 53 195 194 193 162 113
2021/2022810 49 153 31 32 9 46 33 62 34 80 92 189
2022/2023866 125 10 30 63 90 212 7 99 132 21 39 38
2023/2024967 63 20 91 60 57 177 46 50 185 20 32 166
2024/20252.168 15 36 35 257 238 156 231 103 247 158 395 297
2025/20262.463 393 511 307 689 495 68 0 0 0 0 0 0
Totale 13.912